Glucophage tablets are taken by mouth with or after food to help control blood glucose in adults with Type 2 diabetes. Its active ingredient, metformin, lowers glucose production in the liver and helps the body respond better to insulin.
Metformin is prescribed mainly for Type 2 diabetes, alongside dietary measures and physical activity when these do not provide sufficient glycaemic control alone.
Type 2 diabetes involves insulin resistance, increased glucose release from the liver and, over time, reduced insulin production by pancreatic beta cells. Metformin addresses the first two problems without replacing insulin directly.
Metformin lowers glucose production in the liver and improves the body's response to insulin. This helps tissues use circulating glucose more effectively and reduces blood glucose levels. It addresses insulin resistance and increased hepatic glucose release without replacing insulin directly.
Glucophage is not suitable for you if a prescriber has identified severe kidney impairment, acute metabolic acidosis or diabetic ketoacidosis.
It also requires careful review during conditions that can reduce oxygen delivery to tissues or cause rapid loss of kidney function.
Kidney function should be reviewed before treatment and during long-term use. Older adults, people with chronic kidney disease and those taking medicines that affect renal function may need more frequent monitoring.
Pregnancy and breastfeeding require an individual treatment decision. Metformin may be used in some pregnancy-related diabetes plans, but the choice depends on glucose control, kidney function and obstetric assessment. It should not be started, stopped or changed during pregnancy without a specific treatment plan.
Digestive symptoms are the most frequent adverse effects associated with metformin. They are often strongest during the first days or weeks of treatment and may lessen after gradual dose adjustment.
Common effects include:
Taking Glucophage with food can reduce stomach irritation. A slow dose increase, a temporary dose reduction or a modified-release formulation may improve tolerance when gastrointestinal symptoms persist. Persistent diarrhoea should not simply be accepted as normal, since it can cause dehydration and affect kidney function.
Long-term metformin treatment can reduce vitamin B12 absorption. Low vitamin B12 may contribute to tiredness, a sore or smooth tongue, pins and needles, numbness, balance problems or anaemia. The MHRA advises clinicians to consider measuring vitamin B12 in patients with symptoms or risk factors, including prolonged treatment and higher daily exposure [1].
Lactic acidosis is rare but serious. Warning symptoms can include marked weakness, unusual sleepiness, vomiting, abdominal pain, muscle cramps, breathing difficulty, feeling cold, dizziness or a slow heartbeat. The risk is higher with significant kidney impairment, severe dehydration, uncontrolled diabetes, serious infection, tissue hypoxia or heavy alcohol intake.
Glucophage can also cause taste disturbance without any change in blood glucose. Patients sometimes stop treatment because of this symptom before discussing practical options such as taking the tablet with food or changing the formulation.
The active ingredient is metformin. It belongs to the biguanide group of medicines and is used to reduce elevated blood glucose in Type 2 diabetes.
Glucophage tablets are swallowed rather than injected. The treatment plan may use metformin alone or combine it with insulin or another glucose-lowering medicine when one treatment does not achieve the intended blood glucose range.
The amount of Glucophage used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist. Dose increases are usually gradual because gastrointestinal adverse effects are more likely when treatment starts at a higher dose.
Typical administration principles include:
A missed dose is usually managed by skipping it rather than doubling the next dose. Double dosing can increase nausea, diarrhoea and the risk of clinically significant metformin accumulation when kidney function is impaired.
Kidney function is assessed before treatment and periodically afterwards. Metformin is cleared mainly through the kidneys, so the dose or continued use may need review when renal function declines.
| Treatment approach | Main action | Main limitation |
|---|---|---|
| Metformin | Reduces liver glucose production and improves insulin sensitivity | Gastrointestinal effects; renal function limits use |
| Insulin | Replaces or supplements insulin directly | Hypoglycaemia and weight gain are possible |
| Insulin secretagogue | Encourages pancreatic insulin release | Hypoglycaemia and weight gain may occur |
Metformin is often selected early in Type 2 diabetes because it targets insulin resistance and rarely causes hypoglycaemia on its own. Insulin may be needed when pancreatic insulin production is inadequate, during severe hyperglycaemia, pregnancy in some circumstances, or acute illness. Secretagogues can lower glucose effectively, but their action continues even when food intake is reduced, which raises hypoglycaemia risk.
The choice depends on HbA1c, kidney function, cardiovascular and kidney disease, weight, age, concurrent medicines and the person’s ability to follow the dosing schedule. NICE guidance supports individualised treatment rather than one fixed regimen for every adult with Type 2 diabetes [2].
Several habits reduce the benefit of treatment or increase avoidable adverse effects:
One practical error is swallowing a modified-release tablet after crushing it to make it easier to take. Altering the tablet can change how metformin is released and may worsen gastrointestinal effects.
Another is measuring success by a single reading. HbA1c reflects average glycaemia over roughly two to three months, while home readings show shorter-term patterns.
In clinical practice, doctors often view metformin as a foundation treatment because it lowers hepatic glucose production without directly forcing insulin release. That profile explains its low hypoglycaemia risk when used alone, though it does not remove the risk created by other diabetes medicines.
Prescribers usually focus on four practical questions: Is kidney function adequate? Is the patient eating and drinking normally? Are gastrointestinal symptoms manageable? Is the HbA1c response sufficient after an appropriate trial?
A clinician may also review vitamin B12 when symptoms develop or when long-term treatment includes recognised risk factors. The MHRA’s 2022 safety communication placed greater emphasis on recognising reduced B12 as a common adverse effect rather than treating it as an unusual finding .
Patients often expect a noticeable sensation after taking a glucose-lowering tablet. Metformin usually does not produce a feeling of immediate action. Its benefit is assessed through blood glucose records and HbA1c rather than through a rapid subjective effect.
Kidney function, liver disease, alcohol intake, dehydration risk, pregnancy, breastfeeding and every current medicine should be discussed before starting treatment. The prescriber should also know about planned procedures involving iodinated contrast. NICE guidance available in 2026 continues to support individualised diabetes treatment based on renal function, HbA1c and comorbidities. Metformin is unsuitable in diabetic ketoacidosis and established metabolic acidosis.
Glucophage used alone does not usually impair concentration or driving because it rarely causes hypoglycaemia by itself. The risk changes when it is combined with insulin or an insulin secretagogue, because low glucose can cause blurred vision, confusion or delayed reactions. The DVLA and NHS advice in 2026 supports checking how diabetes treatment affects an individual before driving. Beta-blockers may mask tremor and palpitations, so additional caution is needed when hypoglycaemia risk is present.
Severe weakness, repeated vomiting, abdominal pain, breathing difficulty, unusual drowsiness, feeling cold, dizziness or a slow heartbeat can signal lactic acidosis and require urgent assessment. Severe dehydration from vomiting or diarrhoea also needs prompt medical advice because kidney function may deteriorate. The MHRA's 2022 safety guidance identifies lactic acidosis as rare but serious, with higher risk in renal impairment and acute illness. Do not take another dose while seeking urgent advice unless an emergency clinician gives different instructions.
The best time depends on the prescribed schedule and whether the formulation is immediate-release or modified-release. Tablets are generally taken with or immediately after meals to reduce nausea, cramping and diarrhoea. NHS diabetes advice in 2026 continues to emphasise matching dosing with meals and the prescribed frequency. A missed dose should not be replaced by taking two doses together.
Yes, diarrhoea is a recognised metformin adverse effect, especially when treatment begins or the dose increases. It often improves when the medicine is taken with food and the dose is increased gradually. The EMA's 2019 product information identifies gastrointestinal symptoms as common or very common depending on the formulation. Persistent or severe diarrhoea can cause dehydration and needs clinical review.
Older adults can use metformin when kidney function and general health support its use. Age itself is not an automatic reason to avoid treatment, but renal function may decline silently and should be monitored. The WHO diabetes framework in 2023 emphasised adapting diabetes care to comorbidity, functional status and treatment burden. Frailty, dehydration, poor food intake and medicines affecting the kidneys require extra caution.
Metformin begins influencing glucose production after treatment starts, but the measurable effect develops over days to weeks as the dose is adjusted and taken consistently. HbA1c is usually reviewed after about three months because it reflects longer-term glucose exposure. NICE guidance in 2026 continues to use HbA1c and home glucose patterns to judge treatment response. A lack of immediate sensation does not mean the medicine is inactive.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Glucophage with my evening meal and found my morning readings became steadier over the following weeks. The tablets fitted into my routine, and I felt more confident managing my Type 2 diabetes.
After using Glucophage consistently, my readings were less erratic than they had been before. I liked that it did not make me feel suddenly low when I took it with food.
Glucophage helped my readings, but the first couple of weeks were uncomfortable because of loose stools and a metallic taste. The benefit was only partial for me, so I discussed the symptoms and my results with my doctor rather than continuing unchanged.
